

Elena Y Klyosova

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3134663/publications.pdf>

Version: 2024-02-01

14
papers

98
citations

1684188
5
h-index

1372567
10
g-index

14
all docs

14
docs citations

14
times ranked

39
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacogenetic loci for rosuvastatin are associated with intima-media thickness change and coronary artery disease risk. <i>Pharmacogenomics</i> , 2022, 23, 15-34.	1.3	5
2	Comprehensive Statistical and Bioinformatics Analysis in the Deciphering of Putative Mechanisms by Which Lipid-Associated GWAS Loci Contribute to Coronary Artery Disease. <i>Biomedicines</i> , 2022, 10, 259.	3.2	7
3	Genetic variation at the catalytic subunit of glutamate cysteine ligase contributes to the susceptibility to sporadic colorectal cancer: a pilot study. <i>Molecular Biology Reports</i> , 2022, , 1.	2.3	2
4	Association between RAC1 gene variation, redox homeostasis and type 2 diabetes mellitus. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13792.	3.4	10
5	The Impact of Genetic Polymorphisms in Glutamate-Cysteine Ligase, a Key Enzyme of Glutathione Biosynthesis, on Ischemic Stroke Risk and Brain Infarct Size. <i>Life</i> , 2022, 12, 602.	2.4	8
6	Polymorphic Variants in gamma-glutamyltransferase 6 as New Genetic Markers of Type 2 Diabetes Mellitus. <i>Metabolism: Clinical and Experimental</i> , 2021, 116, 154537.	3.4	1
7	The Link between Type 2 Diabetes Mellitus and the Polymorphisms of Glutathione-Metabolizing Genes Suggests a New Hypothesis Explaining Disease Initiation and Progression. <i>Life</i> , 2021, 11, 886.	2.4	15
8	Polymorphic variants of glutathione reductase – new genetic markers of predisposition to type 2 diabetes mellitus. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 1164-1170.	0.8	3
9	Genetic variants in glutamate cysteine ligase confer protection against type 2 diabetes. <i>Molecular Biology Reports</i> , 2020, 47, 5793-5805.	2.3	14
10	Apolipoprotein E gene polymorphisms: a relationship with the risk of coronary artery disease and the effectiveness of lipid-lowering therapy with rosuvastatin. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2020, 19, 17-23.	1.4	0
11	Apolipoprotein E gene polymorphisms: a relationship with the risk of coronary artery disease and the effectiveness of lipid-lowering therapy with rosuvastatin. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2020, 19, 17-23.	1.4	2
12	Matrix metalloproteinases as target genes for gene regulatory networks driving molecular and cellular pathways related to a multistep pathogenesis of cerebrovascular disease. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 16467-16482.	2.6	27
13	rs7412 APOE ε ₄ ε ₄ genotype is associated with increased risk of type 2 diabetes mellitus in the Russian population. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 16467-16482.	2.6	27
14	GENETIC AND BIOCHEMICAL INVESTIGATION OF THE GAMMA-GLUTAMYL CYCLOTRANSFERASE ROLE IN PREDISPOSITION TO TYPE 2 DIABETES MELLITUS. <i>Ecological Genetics</i> , 0, , .	0.5	4